$BOMO
bowmo, Inc.

2023 Q1 Form 10-K Financial Statement

#000157587223000553 Filed on April 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $4.476K $36.08K $185.9K
YoY Change
Cost Of Revenue $0.00 $27.40K $75.87K
YoY Change -100.0% 46.92%
Gross Profit $4.476K $8.680K $110.1K
YoY Change -92.67% -26.65%
Gross Profit Margin 100.0% 24.06% 59.19%
Selling, General & Admin $388.0K $963.0K $1.758M
YoY Change 220.25% 694.22% 249.64%
% of Gross Profit 8667.34% 11094.35% 1597.36%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $387.9K $963.0K $1.758M
YoY Change 220.25% 694.23% 249.64%
Operating Profit -$383.5K -$954.3K -$1.600M
YoY Change 538.59% 454.99%
Interest Expense $269.5K -$2.715M $927.1K
YoY Change -385.76% 484.09% -152.09%
% of Operating Profit
Other Income/Expense, Net $1.001M -$2.933M
YoY Change -15372.54% -13204.82%
Pretax Income $617.6K -$3.670M -$4.580M
YoY Change -386.69% 526.07% 194.91%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings $617.6K -$3.670M -$4.600M
YoY Change -386.69% 526.07% 196.17%
Net Earnings / Revenue 13798.97% -10171.29% -2474.14%
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 -$0.15 $0.00
COMMON SHARES
Basic Shares Outstanding 31.30B 24.71B 12.66B
Diluted Shares Outstanding 28.16B 12.66B

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $87.62K $167.1K
YoY Change 3086.18% 2826.44%
Cash & Equivalents $87.62K $167.1K
Short-Term Investments
Other Short-Term Assets $860.00 $860.00
YoY Change
Inventory
Prepaid Expenses
Receivables $0.00 $15.54K
Other Receivables $0.00 $0.00
Total Short-Term Assets $88.47K $183.5K
YoY Change 3117.24% 3113.71%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $88.47K $183.5K
Total Long-Term Assets $0.00 $0.00
Total Assets $88.47K $183.5K
YoY Change 3117.24% 382.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $952.9K $813.4K
YoY Change 191.93% 1135.14%
Accrued Expenses $332.0K $366.6K
YoY Change -79.65% 1870.87%
Deferred Revenue
YoY Change
Short-Term Debt $607.2K $669.6K
YoY Change -28.32% -22.51%
Long-Term Debt Due $303.5K $303.5K
YoY Change 333.63%
Total Short-Term Liabilities $4.645M $5.820M
YoY Change 54.1% 592.89%
LONG-TERM LIABILITIES
Long-Term Debt $260.5K $260.5K
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $260.5K $260.5K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.645M $5.820M
Total Long-Term Liabilities $260.5K $260.5K
Total Liabilities $4.906M $6.080M
YoY Change 62.74% 590.68%
SHAREHOLDERS EQUITY
Retained Earnings -$8.626M -$9.244M
YoY Change 98.22%
Common Stock $313.0K $270.5K
YoY Change 1390.34%
Preferred Stock
YoY Change
Treasury Stock (at cost) $773.5K $773.5K
YoY Change
Treasury Stock Shares $2.917K $2.917K
Shareholders Equity -$4.817M -$5.897M
YoY Change
Total Liabilities & Shareholders Equity $88.47K $183.5K
YoY Change 3117.24% 382.61%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income $617.6K -$3.670M -$4.600M
YoY Change -386.69% 526.07% 196.17%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$79.49K -$195.1K -$617.5K
YoY Change 2585.37% 1837.64% 845.83%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $1.630K $2.150K
YoY Change
Cash From Investing Activities $1.630K $2.150K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid $257.5K
YoY Change
Common Stock Issuance & Retirement, Net $241.5K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 265.5K 782.1K
YoY Change 2555.0% 1001.55%
NET CHANGE
Cash From Operating Activities -79.49K -195.1K -617.5K
Cash From Investing Activities 1.630K 2.150K
Cash From Financing Activities 0.000 265.5K 782.1K
Net Change In Cash -79.49K 72.01K 166.7K
YoY Change -102971.43%
FREE CASH FLOW
Cash From Operating Activities -$79.49K -$195.1K -$617.5K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001381871
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
000-54624
CY2022 dei Entity Registrant Name
EntityRegistrantName
BOWMO, INC.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
WY
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-4144571
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
99 Wall Street
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 891
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10005
CY2022 dei City Area Code
CityAreaCode
212
CY2022 dei Local Phone Number
LocalPhoneNumber
398-0002
CY2022 dei Security12b Title
Security12bTitle
common stock
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
No
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
3125795
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31297119462
CY2022 dei Auditor Name
AuditorName
BF Borgers CPA PC
CY2022 dei Auditor Location
AuditorLocation
Lakewood, CO
CY2022 dei Auditor Firm
AuditorFirmId
5041
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
167103
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
385
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15542
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
37638
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
858
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
0
CY2022Q4 us-gaap Assets Current
AssetsCurrent
183503
CY2021Q4 us-gaap Assets Current
AssetsCurrent
38023
CY2022Q4 us-gaap Assets
Assets
183503
CY2021Q4 us-gaap Assets
Assets
38023
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
813378
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
65853
CY2022Q4 bomo Accrued Expenses Current
AccruedExpensesCurrent
200286
CY2021Q4 bomo Accrued Expenses Current
AccruedExpensesCurrent
286
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
366622
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18602
CY2022Q4 bomo Accrued Officer Compensation
AccruedOfficerCompensation
1074361
CY2021Q4 bomo Accrued Officer Compensation
AccruedOfficerCompensation
556394
CY2022Q4 us-gaap Loans Payable Current
LoansPayableCurrent
113006
CY2021Q4 us-gaap Loans Payable Current
LoansPayableCurrent
0
CY2022Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
190500
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
669581
CY2021Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
84681
CY2022Q4 bomo Preferred Stocks Redemption Premium
PreferredStocksRedemptionPremium
219687
CY2021Q4 bomo Preferred Stocks Redemption Premium
PreferredStocksRedemptionPremium
0
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
2172250
CY2021Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
110992
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3108
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5819671
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
839916
CY2022Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
260494
CY2021Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
40401
CY2022Q4 us-gaap Liabilities
Liabilities
6080165
CY2021Q4 us-gaap Liabilities
Liabilities
880317
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27049736362
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27049736362
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18150000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18150000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
270497
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
18150
CY2022 bomo Common Stock Shares Yet To Be Issued
CommonStockSharesYetToBeIssued
2550000
CY2021 bomo Common Stock Shares Yet To Be Issued
CommonStockSharesYetToBeIssued
0
CY2022Q4 bomo Common Stock Value Yet To Be Issued
CommonStockValueYetToBeIssued
26
CY2021Q4 bomo Common Stock Value Yet To Be Issued
CommonStockValueYetToBeIssued
0
CY2022Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
2917
CY2021Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
0
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
773500
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
0
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3599032
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3802391
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9243925
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4663488
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-5896662
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-842294
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
183503
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
38023
CY2022 us-gaap Revenues
Revenues
185923
CY2021 us-gaap Revenues
Revenues
201675
CY2022 us-gaap Cost Of Revenue
CostOfRevenue
75873
CY2021 us-gaap Cost Of Revenue
CostOfRevenue
51643
CY2022 us-gaap Gross Profit
GrossProfit
110050
CY2021 us-gaap Gross Profit
GrossProfit
150032
CY2022 us-gaap Salaries And Wages
SalariesAndWages
432452
CY2021 us-gaap Salaries And Wages
SalariesAndWages
403738
CY2022 bomo Consulting Expense
ConsultingExpense
181667
CY2021 bomo Consulting Expense
ConsultingExpense
0
CY2022 us-gaap Professional Fees
ProfessionalFees
780251
CY2021 us-gaap Professional Fees
ProfessionalFees
13970
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
363522
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20619
CY2022 us-gaap Operating Expenses
OperatingExpenses
1757892
CY2021 us-gaap Operating Expenses
OperatingExpenses
438327
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-1647842
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-288295
CY2022 us-gaap Interest Expense
InterestExpense
927072
CY2021 us-gaap Interest Expense
InterestExpense
56837
CY2022 us-gaap Debt Instrument Decrease Forgiveness
DebtInstrumentDecreaseForgiveness
0
CY2021 us-gaap Debt Instrument Decrease Forgiveness
DebtInstrumentDecreaseForgiveness
91035
CY2022 bomo Grant Income
GrantIncome
0
CY2021 bomo Grant Income
GrantIncome
6000
CY2022 us-gaap Gain Loss On Condemnation
GainLossOnCondemnation
27856
CY2021 us-gaap Gain Loss On Condemnation
GainLossOnCondemnation
0
CY2022 bomo Initial Recognition Of Derivative Liability
InitialRecognitionOfDerivativeLiability
2578230
CY2021 bomo Initial Recognition Of Derivative Liability
InitialRecognitionOfDerivativeLiability
0
CY2022 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
544850
CY2021 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-17820
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2932596
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
22378
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4580438
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-265917
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-4580438
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-265917
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.01
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.01
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12664533251
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12664533251
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18150000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18150000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-842294
CY2022 bomo Stock Issued During Period Value Reverse Merger Recapitalization
StockIssuedDuringPeriodValueReverseMergerRecapitalization
-3082418
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4719
CY2022 bomo Adjustments To Additional Paid In Capital Distributions To Shareholders
AdjustmentsToAdditionalPaidInCapitalDistributionsToShareholders
-257500
CY2022 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
596927
CY2022 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
2264341
CY2022 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-4580437
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-5896662
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-576427
CY2021 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
50
CY2021 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-265917
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-842294
CY2022 us-gaap Profit Loss
ProfitLoss
-4580438
CY2021 us-gaap Profit Loss
ProfitLoss
-265917
CY2022 bomo Reconciliation Of Debt Balances
ReconciliationOfDebtBalances
145717
CY2022 us-gaap Gain Loss On Investments
GainLossOnInvestments
-197370
CY2022 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
289252
CY2021 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
42457
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
216186
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
50
CY2022 bomo Gain On New Methodology For Accounting For Debt Conversion Features
GainOnNewMethodologyForAccountingForDebtConversionFeatures
27856
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
91035
CY2021 bomo Grant Income
GrantIncome
6000
CY2022 us-gaap Extinguishment Of Debt Amount
ExtinguishmentOfDebtAmount
117565
CY2022 bomo Initial Derivative Expense
InitialDerivativeExpense
2578230
CY2022 bomo Derivative Gain Loss On Derivative Fair Value
DerivativeGainLossOnDerivativeFairValue
-544850
CY2021 bomo Derivative Gain Loss On Derivative Fair Value
DerivativeGainLossOnDerivativeFairValue
17820
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-22098
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
37638
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-139
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
421125
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
13970
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
14380
CY2022 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
483915
CY2022 us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
67123
CY2021 us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
309079
CY2022 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3108
CY2021 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
3108
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-617532
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
274
CY2022 bomo Cash Acquired From Reverse Merger
CashAcquiredFromReverseMerger
517
CY2022 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
1633
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2150
CY2022 bomo Proceeds From Loans Payable
ProceedsFromLoansPayable
269100
CY2022 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
770500
CY2022 us-gaap Payments Of Dividends
PaymentsOfDividends
257500
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
782100
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
166718
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
274
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
385
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
111
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
167103
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
385
CY2022 us-gaap Interest Paid Net
InterestPaidNet
CY2021 us-gaap Interest Paid Net
InterestPaidNet
CY2022 bomo Common Stock Issued For Extinguishment Of Preferred Stock
CommonStockIssuedForExtinguishmentOfPreferredStock
1905322
CY2022 bomo Tangible Assets Acquired In Merger
TangibleAssetsAcquiredInMerger
3082419
CY2022 bomo Equity Acquired In Merger Net
EquityAcquiredInMergerNet
3063589
CY2022 bomo Debt Discount Associated With Issuance Of Warrants And Derivative Liabilities
DebtDiscountAssociatedWithIssuanceOfWarrantsAndDerivativeLiabilities
734853
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
241454
CY2022 us-gaap Stock Issued1
StockIssued1
1000
CY2022 bomo Accrual For Shares To Be Issued For Acquisition Of Interview Mastery
AccrualForSharesToBeIssuedForAcquisitionOfInterviewMastery
200000
CY2022 bomo Consolidation And Basis Of Presentation Policies Textblock
ConsolidationAndBasisOfPresentationPoliciesTextblock
<div style="margin: 0px 0px 0px 0cm; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background: none; text-indent: 0px; line-height: 12pt;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; white-space: pre-wrap; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;;white-space:pre-wrap;"> </div></div> <div style="background: none; margin: 0px 0px 0px 0cm; font-family: &quot;Times New Roman&quot;, Times, serif;;text-indent: 0px;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-style:italic;display:inline;"><div style="text-decoration:underline;display:inline;"><div style="font-size: 10pt; color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; background: none; letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;">Principles of Consolidation and Basis of Presentation</div></div></div></div><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration:underline;display:inline;"><div style="font-size: 10pt; color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; background: none; letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;"/></div></div></div></div> <div style="background: none; margin: 0px 0px 0px 0cm; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 0px; line-height: 12pt;"><div style="font-size: 10pt; color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; white-space: pre-wrap; background: none; letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;;white-space:pre-wrap;"> </div></div> <div style="margin: 0px 0px 0px 0cm; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background: none; text-indent: 0px; line-height: 12pt;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;">The consolidated financial statements include the accounts of bowmo, Inc. and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</div></div>
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin: 0px 0px 0px 0cm; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background: none; text-indent: 0px; line-height: 12pt;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; color: rgb(0, 0, 0); white-space: pre-wrap; background: none; letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;;white-space:pre-wrap;"> </div></div> <div style="margin: 0px 0px 0px 0cm; text-align: justify; line-height: normal; font-family: &quot;Times New Roman&quot;, Times, serif; background: none;;text-indent: 0px;"><div style="font-style:italic;display:inline;"><div style="text-decoration:underline;display:inline;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;">Use of Estimates</div></div></div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;"/></div> <div style="margin: 0px 0px 0px 0cm; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background: none; text-indent: 0px; line-height: 12pt;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; white-space: pre-wrap; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;;white-space:pre-wrap;"> </div></div> <div style="margin: 0px 0px 0px 0cm; text-align: justify; line-height: normal; font-family: &quot;Times New Roman&quot;, Times, serif; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;">The preparation of financial statements in conformity with generally accepted accounting principles</div><div style="font-family: &quot;Times New Roman&quot;, Times, serif; white-space:pre-line; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;">(“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</div></div>
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
185923
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
201675
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="background: none; margin: 0px 0px 0px 0cm; text-align: justify; line-height: normal; font-family: &quot;Times New Roman&quot;, Times, serif;;text-indent: 0px;"><div style="font-style:italic;display:inline;"><div style="text-decoration:underline;display:inline;"><div style="font-size: 10pt; background: none; font-family: &quot;Times New Roman&quot;, Times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;">Concentrations of credit risk</div></div></div><div style="font-style:italic;display:inline;"><div style="text-decoration:underline;display:inline;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;"/></div></div></div><div style="background: none; margin: 0px 0px 0px 0cm; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 0px; line-height: 12pt;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; color: rgb(0, 0, 0); white-space: pre-wrap; background: none; letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;;white-space:pre-wrap;"> </div></div><div style="background: none; margin: 0px 0px 0px 0cm; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 0px; line-height: 12pt;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;">Financial instruments which potentially subject the Company to credit risks consist primarily of cash and cash equivalents, and accounts receivable. Cash and cash equivalents are held in United States financial institutions. At times such amounts may exceed federally insured limits.</div></div><div style="background: none; margin: 0px 0px 0px 0cm; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 0px; line-height: 12pt;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; color: rgb(0, 0, 0); white-space: pre-wrap; background: none; letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;;white-space:pre-wrap;"> </div></div><div style="background: none; margin: 0px 0px 0px 0cm; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 0px; line-height: 12pt;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;">As of December 31, 2022, one customer accounted for 100% of accounts receivable. As of December 31, 2021, two customers accounted for more than 10% of accounts receivable, at 80% and 19%, for a total of 99%.</div></div><div style="background: none; margin: 0px 0px 0px 0cm; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 0px; line-height: 12pt;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; color: rgb(0, 0, 0); white-space: pre-wrap; background: none; letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;;white-space:pre-wrap;"> </div></div><div style="background: none; margin: 0px 0px 0px 0cm; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 0px; line-height: 12pt;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;">During the year ended December 31, 2022, <div style="text-indent: 0px; letter-spacing: 0px; top: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; background: none; color: rgb(0, 0, 0);;display:inline;">five<div style="letter-spacing: 0px; top: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; background: none; color: rgb(0, 0, 0);;display:inline;"> </div></div>customers accounted for more than 10% of revenue, at 47%, 19%, 13%, 11%, and 10%, for a total of 100%. During the year ended December 31, 2021, two customers accounted for more than 10% of revenue, at 80% and 19%, for a total of 99%.</div></div>
CY2022 us-gaap Gain Loss On Condemnation
GainLossOnCondemnation
27856
CY2022 bomo Going Concern
GoingConcern
<div style="margin: 0px 0px 0px 0cm; text-align: justify; line-height: normal; font-family: &quot;Times New Roman&quot;, Times, serif; background: none;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;">NOTE 3 – GOING CONCERN</div></div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;"/></div><div style="margin: 0px 0px 0px 0cm; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background: none; text-indent: 0px; line-height: 12pt;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; white-space: pre-wrap; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;;white-space:pre-wrap;"> </div></div><div style="margin: 0px 0px 0px 0cm; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background: none; text-indent: 0px; line-height: 12pt;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;">The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles which contemplate continuation of the Company as a going-concern basis. The going concern basis assumes that assets are realized, and liabilities are extinguished in the ordinary course of business at amounts disclosed in the consolidated financial statements. The Company has incurred recurring losses from operation<div style="letter-spacing: 0px; top: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; background: none; color: rgb(0, 0, 0);;display:inline;">s</div>. <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; background: none; letter-spacing: 0px; top: 0px;;display:inline;">The Company has an accumulated deficit of approximately $9.2 million, and a net loss for the year ended December 31, 2022, of $4.6 million. Of the loss, approximately $1.6 million was due to operations and the remainder was due primarily to interest expense and the derivative liabilities. </div>The Company’s ability to continue as a going concern depends upon its ability to obtain adequate funding to support its operations through continuing investments of debt and/or equity by qualified investors/creditors, internally generated working capital and monetization of intellectual property assets. These factors raise substantial doubt about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Management is currently pursuing a business strategy which includes raising the necessary funds to finance the Company’s development and marketing efforts.<div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; background: none; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div>
CY2022Q4 us-gaap Retained Earnings Appropriated
RetainedEarningsAppropriated
9200000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-4600000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-1600000
CY2022 us-gaap Business Combination Separately Recognized Transactions Additional Disclosures Acquisition Cost Expensed
BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed
58092
CY2021 us-gaap Business Combination Separately Recognized Transactions Revenues And Gains Recognized
BusinessCombinationSeparatelyRecognizedTransactionsRevenuesAndGainsRecognized
14692
CY2021 us-gaap Business Combination Separately Recognized Transactions Net Gains And Losses
BusinessCombinationSeparatelyRecognizedTransactionsNetGainsAndLosses
21862
CY2022Q4 us-gaap Business Combination Separately Recognized Transactions Revenues And Gains Recognized
BusinessCombinationSeparatelyRecognizedTransactionsRevenuesAndGainsRecognized
13059
CY2022Q4 us-gaap Business Combination Separately Recognized Transactions Net Gains And Losses
BusinessCombinationSeparatelyRecognizedTransactionsNetGainsAndLosses
15279
CY2022 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
198982
CY2021 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
216367
CY2022 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-4595717
CY2021 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-287779
CY2022 us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
0
CY2022 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
0
CY2021 us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
-0.02
CY2021 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-0.02
CY2022Q4 us-gaap Other Loans Payable
OtherLoansPayable
564000
CY2021Q4 us-gaap Other Loans Payable
OtherLoansPayable
40400
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
260494
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
6807
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
7066
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
7336
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
7616
CY2022Q4 bomo Long Term Debt Maturity Repayments Year Five And Thereafter
LongTermDebtMaturityRepaymentsYearFiveAndThereafter
274681
CY2022Q4 us-gaap Other Loans Payable
OtherLoansPayable
564000
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
1197681
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
84681
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
528100
CY2021Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
0
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
669581
CY2021Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
84681
CY2022 bomo Gain On New Methodology For Accounting For Debt Conversion Features
GainOnNewMethodologyForAccountingForDebtConversionFeatures
27856
CY2022 us-gaap Premiums Earned Net
PremiumsEarnedNet
1197681
CY2022Q4 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
219687
CY2020Q4 us-gaap Derivative Instruments And Hedges Liabilities
DerivativeInstrumentsAndHedgesLiabilities
93172
CY2021 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
0
CY2021 bomo Changes In Derivative Liability Due To Exercise Or Redemption
ChangesInDerivativeLiabilityDueToExerciseOrRedemption
0
CY2021 bomo Derivative Gain Loss On Derivative Fair Value
DerivativeGainLossOnDerivativeFairValue
17820
CY2021Q4 us-gaap Derivative Instruments And Hedges Liabilities
DerivativeInstrumentsAndHedgesLiabilities
110992
CY2022 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
2718645
CY2022 bomo Changes In Derivative Liability Due To Exercise Or Redemption
ChangesInDerivativeLiabilityDueToExerciseOrRedemption
-112537
CY2022 bomo Derivative Gain Loss On Derivative Fair Value
DerivativeGainLossOnDerivativeFairValue
-544850
CY2022Q4 us-gaap Derivative Instruments And Hedges Liabilities
DerivativeInstrumentsAndHedgesLiabilities
2172250
CY2021Q4 us-gaap Share Price
SharePrice
0.1
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.05
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P0Y7M28D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.83
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0039
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27049736362
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18150000
CY2022 bomo Extinguishment Of Convertible Debt
ExtinguishmentOfConvertibleDebt
18094721962
CY2022Q4 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
18094721962
CY2022Q4 bomo Debt Instrument Face Value
DebtInstrumentFaceValue
572400
CY2022 us-gaap Debt Instrument Increase Decrease Other Net
DebtInstrumentIncreaseDecreaseOtherNet
1332922
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
117565
CY2022Q4 bomo Total Debt Current
TotalDebtCurrent
2022887
CY2021Q4 bomo Share Available To Purchase With Stock Warrants Outstanding Number
ShareAvailableToPurchaseWithStockWarrantsOutstandingNumber
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
5616000000
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.0001
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.6
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0
CY2022 bomo Weighted Average Price Forfeited
WeightedAveragePriceForfeited
0
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0
CY2022 bomo Weighted Average Fair Value Expired
WeightedAverageFairValueExpired
0
CY2022Q4 bomo Share Available To Purchase With Stock Warrants Outstanding Number
ShareAvailableToPurchaseWithStockWarrantsOutstandingNumber
5616000000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.0001
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
6.6
CY2022Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
5616000000
CY2022 bomo Weighted Average Price Exercisable
WeightedAveragePriceExercisable
0.0001
CY2022 bomo Weighted Average Fair Value Exercisable Outstanding
WeightedAverageFairValueExercisableOutstanding
6.66
CY2022 bomo Number Outstanding In Shares
NumberOutstandingInShares
5616000000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P6Y7M6D
CY2022 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
0.0001
CY2022 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
40875
CY2021 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
50500
CY2019Q3 bomo Salary Per Month
SalaryPerMonth
10000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
532000
CY2022 bomo Amount Of Indebtedness
AmountOfIndebtedness
1200000
CY2017Q1 bomo Obtained Default Judgment
ObtainedDefaultJudgment
27084
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
2923000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
1148000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
245000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
243000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
193000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
193000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
3361000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
1584000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
3361000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1584000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.1529
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.1822
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.025
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.0626
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.3879
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.4548
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020Q1 bomo Coronavirus Aid Relief And Economic Security Act Relief Package Amount
CoronavirusAidReliefAndEconomicSecurityActReliefPackageAmount
2
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2021 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2022 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2021 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1777000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
120000

Files In Submission

Name View Source Status
0001575872-23-000553-index-headers.html Edgar Link pending
0001575872-23-000553-index.html Edgar Link pending
0001575872-23-000553.txt Edgar Link pending
0001575872-23-000553-xbrl.zip Edgar Link pending
bomo-20221231.htm Edgar Link pending
bomo-20221231.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nm035_ex31.htm Edgar Link pending
nm035_ex32.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
bomo-20221231_cal.xml Edgar Link unprocessable
bomo-20221231_pre.xml Edgar Link unprocessable
bomo-20221231_lab.xml Edgar Link unprocessable
bomo-20221231_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bomo-20221231_htm.xml Edgar Link completed
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending